Soligenix, Inc. (SNGX)

Market Cap	7.40M
Revenue (ttm)	364,183
Net Income (ttm)	-7.10M
Shares Out	2.51M
EPS (ttm)	-5.94
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	47,414
Open	3.000
Previous Close	3.105
Day's Range	2.930 - 3.000
52-Week Range	1.830 - 19.200
Beta	1.75
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 8, 2024

About SNGX

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inf...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 15, 1987
• Employees: 15
• Stock Exchange: NASDAQ
• Ticker Symbol: SNGX
• Website: https://www.soligenix.com

Financial Performance

In 2023, Soligenix's revenue was $839,359, a decrease of -11.55% compared to the previous year's $948,911. Losses were -$6.14 million, -55.50% less than in 2022.